Valeria Merz

Trento, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

Journal: NPJ precision oncology

Published: May 22, 2026

Two lenses, same picture: Interpreting nal-IRI in biliary tract cancer.

Two lenses, same picture: Interpreting nal-IRI in biliary tract cancer.

Journal: Journal of hepatology

Published: October 04, 2025

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.

Journal: ESMO open

Published: October 03, 2025

Editorial: Molecular markers for pancreatic cancers: new technologies and applications in the clinical practice.

Editorial: Molecular markers for pancreatic cancers: new technologies and applications in the clinical practice.

Journal: Frontiers in oncology

Published: June 22, 2025

One-step diagnosis and treatment of an atypical large granular cell tumor of the colon.

One-step diagnosis and treatment of an atypical large granular cell tumor of the colon.

Journal: iGIE : innovation, investigation and insights

Published: April 03, 2025

Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma.

Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 28, 2024

Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma.

Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma.

Journal: Journal of cancer research and clinical oncology

Published: May 10, 2024

CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages.

Journal: NPJ precision oncology

Published: April 24, 2024

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 17, 2023

Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.

Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: August 31, 2023

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.

Journal: Therapeutic advances in medical oncology

Published: August 09, 2023

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.

Journal: Journal of personalized medicine

Published: May 02, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026